modelPovidoneIodine
Extends from Pharmacolibrary.Drugs.ATC.S.S01AX18.
Information
| name: | PovidoneIodine | |
| ATC code: | S01AX18 | route: | topical |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Povidone-iodine is a broad-spectrum antiseptic used for skin disinfection before and after surgery, and for the treatment and prevention of infections in wounds. Its use as a topical antimicrobial agent is widespread in hospital and community settings. It is not administered systemically for therapeutic purposes and is not approved for internal use.
Pharmacokinetics
There are no pharmacokinetic studies detailing systemic absorption, distribution, clearance, or compartmental modeling following ophthalmic or topical application in humans. Systemic absorption is reported to be minimal after topical application in intact skin, but can increase with use on large wounds or mucous membranes.
References
Lin, YS, et al., & Milgrom, P (2018). Pharmacokinetics of Iodine and Fluoride following Application of an Anticaries Varnish in Adults. JDR clinical and translational research 3(3) 238–245. DOI:10.1177/2380084418771930 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30938600
Below, H, et al., & Rudolph, P (2006). Systemic iodine absorption after preoperative antisepsis using povidone-iodine in cataract surgery-- an open controlled study. Dermatology (Basel, Switzerland) 212 Suppl 1 41–46. DOI:10.1159/000089198 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16490974
Tahirović, H, et al., & Gnat, D (2009). Maternal and neonatal urinary iodine excretion and neonatal TSH in relation to use of antiseptic during caesarean section in an iodine sufficient area. Journal of pediatric endocrinology & metabolism : JPEM 22(12) 1145–1149. DOI:10.1515/jpem.2009.22.12.1145 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20333874
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)